RxDoctor Payments Data

Alice David, MD

Hematology & Oncology · Augusta, GANPI 1780661066

Payments from drug & device makers

$33,131in general payments, 2019–2025

Across 1,241 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • Novartis$2K
  • Merck$2K
  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$5502%
  • Food & beverage$20,95392%
  • Education$1,2756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer54$10,978
Novartis106$2,020
Merck86$1,760
Johnson & Johnson99$1,686
E.r. Squibb & Sons, L.L.C.120$1,503
AstraZeneca(2 entities)74$1,342
Daiichi Sankyo Inc.37$1,316
Genentech USA, Inc.60$1,210
Sanofi39$784
Gilead(2 entities)46$736
Incyte Corporation20$566
Astellas Pharma US Inc24$563
Bristol Myers Squibb34$555
GSK28$485
AbbVie25$443
Puma Biotechnology, Inc.22$435
Exelixis Inc.19$429
Seagen Inc.24$413
Eisai Inc.22$410
Pharmacyclics LLC, An Abbvie Company21$365
Stemline Therapeutics Inc.13$310
Regeneron Healthcare Solutions, Inc.15$273
Takeda Pharmaceuticals U.S.A., Inc.13$273
Array Biopharma Inc21$258
Jazz Pharmaceuticals Inc.13$239
Lilly USA, LLC13$237
Beigene USA, Inc.14$236
Bayer12$210
Octapharma USA, Inc.3$201
AVEO Pharmaceuticals, Inc.12$199
EMD Serono, Inc.13$188
Karyopharm Therapeutics Inc.8$158
AMAG Pharmaceuticals, Inc.10$154
Ipsen Biopharmaceuticals, Inc7$140
Boehringer Ingelheim6$135
Deciphera Pharmaceuticals Inc.6$108
Rigel Pharmaceuticals, Inc.7$104
Blueprint Medicines Corporation5$95
Tersera Therapeutics LLC4$83
Sanofi-aventis U.S. LLC1$80
Taiho Oncology, Inc.3$72
Clovis Oncology, Inc.6$68
Springworks Therapeutics, Inc.3$66
Acrotech Biopharma Inc.3$63
Adaptive Biotechnologies Corporation4$62
Coherus Oncology, Inc.3$60
Mirati Therapeutics, Inc.4$59
Spectrum Pharmaceuticals Inc.3$58
Fennec Pharmaceuticals, Inc.2$56
ADC Therapeutics America, Inc.3$46
Pharmaessentia USA Corporation3$45
Beone Medicines USA, Inc.2$44
Myovant Sciences Inc.3$43
Pharmacosmos Therapeutics Inc.2$40
Amgen2$34
Morphosys, US Inc.2$33
Tesaro, Inc.2$31
Sobi, Inc2$30
Secura Bio, Inc.2$28
Epizyme, Inc.2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,131 in reported general payments places this provider in the 70th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$4,570,184
Medicare patients
1,076
Services billed
259,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate21$455,828
Lenalidomide34$405,034
CabometyxCabozantinib S-Malate11$281,051
EliquisApixaban14$8,371
Anastrozole455$7,760
Exemestane75$5,565
Imatinib Mesylate22$4,298
Letrozole186$2,958
Ondansetron Hcl31$2,784
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen58$2,196
Fentanyl12$1,712
Hydroxyurea28$925
Morphine Sulfate ErMorphine Sulfate18$483
Oxycodone Hcl22$414
Lidocaine-PrilocaineLidocaine/Prilocaine20$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$1,342$455,82821 claims
Exelixis Inc.Cabometyx$429$281,05111 claims
PfizerEliquis$10,978$8,37114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →